Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 25, 2021
Context: This filing serves to distribute two press releases issued on the filing date. The first provides a data update regarding the COM701 Phase 1 clinical trial. The second reports the Company's financial results for the fourth quarter and full year ended December 31, 2020.
Key Financial Metrics
The provided text references the issuance of a press release containing fourth quarter and full year 2020 financial results (Exhibit 99.2) but does not contain the specific numerical data within the filing body itself. Consequently, the following metrics are not available in the source text:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Note: Specific financial values are not present in the provided text; they are contained in the referenced Exhibit 99.2.
Material Changes
The filing does not provide comparative financial data to quantify material changes versus prior periods. The primary material event disclosed is the clinical data update for the COM701 Phase 1 trial, which is incorporated by reference from the attached press release.
Guidance, Outlook, and Risks
Clinical Development: The Company announced a data update for its COM701 Phase 1 clinical trial. Specific details regarding the data, safety, or efficacy are not included in the text of this Form 6-K but are referenced in Exhibit 99.1.
Forward-Looking Statements: The filing notes that the "Forward-Looking Statement" section of the clinical trial press release is incorporated by reference into the Company's Registration Statement on Form F-3.
Legal Disclaimer: The information furnished in this report (including the financial results in Exhibit 99.2) is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 for specific clinical data, safety profiles, and trial status of the COM701 Phase 1 study.
- Review Exhibit 99.2 for the actual numerical values of Q4 and full-year 2020 revenue, expenses, and cash position.
- Verify the incorporation of forward-looking statements into the Form F-3 Registration Statement (File No. 333-240183).
- Confirm the status of the COM701 trial timeline and any subsequent regulatory interactions not detailed in this summary.